
Areas of Expertise
Conditions I Treat
- Colon cancer
- Rectal cancer
- Anal cancer
My Specialties
- Clinical trials
- Immunotherapy
How This MSK Center Takes Care of Younger Patients With Colorectal and Gastrointestinal Cancers
Get to Know Me
I am a physician-scientist and medical oncologist specializing in the treatment of patients with gastrointestinal (GI) cancers, particularly colorectal cancer, appendiceal (appendix) cancer, and bile duct cancer (cholangiocarcinoma). I see patients at Rockefeller Outpatient Pavilion in New York City.
I am the Section Head of Colorectal Cancer and also the founder and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancer at Memorial Sloan Kettering Cancer Center (MSK). This clinic — the first of its kind in the world — is dedicated solely to the specific needs of people under 50 who have colorectal or other GI cancers.
This research and patient care center provides coordinated and holistic care that focuses on concerns including quality of life during and after treatment, preserving fertility, and the long-term effects of surviving cancer.
Another important aim of our center is to answer the question of why cancer is becoming more prevalent in a younger generation, identify who is at risk, and how we can better screen them and prevent this cancer from occurring at such a young age. This MSK-led research has inspired centers worldwide and spurred national and international collaborations.
Read more
My research is focused on novel biomarker-driven, therapeutic approaches and treatments for colorectal cancer and other GI malignancies. I design and execute multidisciplinary clinical trials and research initiatives with the goals of advancement of science and improvement in patient outcomes and quality of life.
Some of my current research is focused on investigating if the body’s own immune system could be deployed to attack cancer cells in early-stage rectal cancer, using a form of immunotherapy called a checkpoint inhibitor. We’ve seen great success with this type of immunotherapy in mismatch repair deficient tumors—tumors that form when the DNA mismatch repair system is unable to repair mistakes that happen during cell division—and are continuing to expand clinical trials to target other biomarkers. The goal of this work is to help people overcome cancer while preserving their quality of life and avoiding surgery, radiation, and chemotherapy.
In addition to my research and clinical care, I am a member of the American Society for Clinical Investigation (ASCI) and play an active role and serve as an organizing member of several national and international committees including the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and the American Association for Cancer Research (AACR).
I'm a gastrointestinal (GAS-troh-in-TES-tih-nul) medical oncologist, which is a cancer doctor who specializes in gastrointestinal (GI) cancers. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers. We also treat GI stromal tumors and neuroendocrine tumors.
- Section Head, Colorectal Cancer
- Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers
Conditions I Treat
- Colon cancer
- Rectal cancer
- Anal cancer
- Appendiceal (appendix) cancer and conditions
- Bile duct cancer (cholangiocarcinoma)
My Specialties
- Clinical trials
- Immunotherapy
Education
- MD, New York Medical College
Residencies
- Internal Medicine - New York Presbyterian/Weill Cornell Medical Center
Fellowships
- Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Awards and Honors
- Castle Connolly: America’s Top Doctors (2022-2025)
- TIME100 Most Influential People in Health (2024)
- Castle Connolly: Top Doctors New York Metro Area (2022-2023)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment

Contact and Location
Dr. Cercek sees patients at one location.












Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Cercek
- A Phase 2 Study of Botensilimab and Balstilimab Immunotherapy Before Surgery for Rectal Cancer
- A Phase II Study of Dostarlimab Immunotherapy in People with Locally Advanced "Mismatch Repair-Deficient" Rectal Cancer
- A Phase II Study of Gemcitabine and Oxaliplatin Chemotherapy with or without a Floxuridine and Dexamethasone Pump in People with Inoperable Cholangiocarcinoma
- A Phase II Study of Tucatinib and Trastuzumab Followed by Chemotherapy as Initial Treatment for Locally Advanced HER2-Positive Rectal Cancer
Read more
- A Phase III Study of Tucatinib with Trastuzumab and mFOLFOX6 Chemotherapy versus Standard Care as Initial Treatment for HER2+ Metastatic Colorectal Cancer
- A Study Assessing the Effects of Chemotherapy or Radiation Therapy on Reproductive and Sexual Health in People with Early-Onset Colorectal Cancer
- Clinical Trials Co-Investigated by Dr. Cercek
- A Phase II Study Assessing the Addition of Irinotecan to Combination Chemotherapy after Chemoradiation in Patients with Stage II or III Rectal Cancer to Improve the Rate of Complete Response

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Cercek’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
5.0 203 reviews
- 4.9 Provider's Explanations Easy to Understand
- 4.9 Trusts Provider with Care
- 4.9 Provider Listened Carefully
- 5.0 Likelihood of Recommending Provider
Always treated with respects
she is an excellent doctor. However, I waited 30 minutes for the appointment to start and I finally had to call the office to know what was going on. If she is going to run so late on a video appointment, the least you can do is to give timely updates about when the appointment will start.
Love Dr Cercek
My team, Dr. Cercek, Dr. Williams, and Joe, are just wonderful. I can't put into words of how great they are.
Memorial Sloan Kettering is an outstanding hospital. I've received great care. Dr. Cercek is wonderful. She's personable. She's smart. She explains everything that I can understand. She listens carefully. She doesn't rush through the appointment at all. And I feel very, very fortunate to have been treated at Memorial Sloan Kettering.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Andrea Cercek discloses the following relationships and financial interests:
-
AbbVie
Professional Services and Activities -
Agenus Inc.
Professional Services and Activities -
Amgen
Professional Services and Activities -
Daiichi Sankyo
Professional Services and Activities -
GlaxoSmithKline
Professional Services and Activities -
Haystack Oncology, Inc.
Equity
-
Illumina
Professional Services and Activities -
Janssen Oncology, Inc.
Professional Services and Activities -
Merck & Co Inc.
Professional Services and Activities -
Regeneron Pharmaceuticals, Inc.
Professional Services and Activities -
Roche Diagnostics Asia Pacific Pte Ltd
Professional Services and Activities -
Seagen
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.